Barclays lowered the firm’s price target on Iqvia to $255 from $275 and keeps an Overweight rating on the shares ahead of the Q2 report. The analyst says the company’s intra-quarter commentary has lowered expectations for a bioprocessing destocking recovery, biotech funding has stalled and capex spending is bouncing along the bottom due to constrained pharma budgets. The firm continues to favor contract research organizations on valuation, and bioprocessing names “as it is still the only market that is improving.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- ‘The CRO Sector Looks Appealing,’ Says Goldman Sachs — Here Are 2 Stocks to Consider
- Dollar Tree downgraded, Lululemon upgraded: Wall Street’s top analyst calls
- Iqvia initiated with a Buy at Goldman Sachs
- Here’s what Wall Street experts are saying about Salesforce ahead of earnings
- IQVIA Holdings Announces Executive Team Reshuffle and Role Change
Questions or Comments about the article? Write to editor@tipranks.com